Faes Farma, S.A. Faes Farma, S.A.

Faes Farma, S.A.

FAE

Rank in Stocks #6367
Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research,... Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international markets. The company's comprehensive product line encompasses prescription drugs, generic alternatives, over-the-counter (OTC) remedies, nutritional supplements, infant formula, and various other health-related items. Among its diverse offerings are Actimag (a magnesium pidolate), the anti-allergic Bilaxten, the anti-infective Bronquidiazina CR, Claversal for ulcerative colitis and Crohn's disease, the corticoid Dezacor, the anti-inflammatory Dolotren (also available as Dolotren Gel), Dynamogen (an anti-anorexic), Ferroprotina (an anti-anaemic), Hidroferol, Lipofen, Positon for dermatological conditions, strength-enhancing products such as Potenciator and Surmenalit, the laxative Pruina, the muscle relaxant and analgesic Robaxisal Compuesto, Trausan (a citicoline-based product), the venous vasoprotector Venosmil (and Venosmil Gel), and the anti-influenza medication Yendol. Furthermore, Faes Farma provides key active pharmaceutical ingredients, including Bilastine (an antihistamine molecule for allergic rhinitis, conjunctivitis, and urticaria), Calcifediol for bone metabolism, Deflazacort for treating osteoarticular diseases, Hidrosmin for venous insufficiency, and Mesalazine for digestive problems. The firm also engages in significant export activities. Founded in 1933, Faes Farma, S.A. is headquartered in Leioa, Spain.
Share Price
$5.48
Last synced: 2026-11-18
Market Cap
$1.71B
Change (1 day)
-0.53%
Change (1 year)
3.14%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Faes Farma, S.A. (FAE)
EPS as of June 2026 TTM: $0.47
According to Faes Farma, S.A.'s latest financial reports, its current EPS (TTM) is $0.47. At the end of 2025 the company had an EPS of $0.31, a decrease compared to its 2024 EPS of $0.37.
EPS history for Faes Farma, S.A. from 2003 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $0.47 52.90%
2025 $0.31 -18.58%
2024 $0.37 12.97%
2023 $0.33 6.59%
2022 $0.31 -2.29%
2021 $0.32 0.57%
2020 $0.32 22.67%
2019 $0.26 18.23%
2018 $0.22 21.28%
2017 $0.18 22.20%
2016 $0.15 13.05%
2015 $0.13 8.58%
2014 $0.12 -6.54%
2013 $0.13 13.63%
2012 $0.11 34.68%
2011 $0.08 -31.29%
2010 $0.12 -14.85%
2009 $0.14 -6.46%
2008 $0.15 -12.60%
2007 $0.18 -11.14%
2006 $0.20 82.78%
2005 $0.11 -14.83%
2004 $0.13 31.13%
2003 $0.10 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$6.03 1,172.13%
DE
$6.01 1,167.47%
DE
$1.53 223.40%
JP
$3.66 672.15%
CH
$0.45 -5.06%
IL

Questions about Faes Farma, S.A.'s earnings per share (EPS)

What is Faes Farma, S.A.'s earnings per share (EPS)?

Faes Farma, S.A.'s earnings per share (EPS) over the last twelve months is $0.47, as of Jun 2026.

What was Faes Farma, S.A.'s earnings per share (EPS) in 2025?

In 2025, Faes Farma, S.A.'s earnings per share (EPS) was $0.31, 16.22% less than in 2024 ($0.37).

How has Faes Farma, S.A.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Faes Farma, S.A.'s earnings per share (EPS) went from $0.32 to $0.31, an average decline of 0.63% a year.

How does Faes Farma, S.A.'s earnings per share (EPS) compare with similar companies?

Faes Farma, S.A.'s earnings per share (EPS) ($0.47) is higher than that of 1 of the 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.03.